Form 4 Filing for Arcellx, Inc. - Officer/Director Transaction

This Form 4 filing reports transactions by Kavita Patel, a director at Arcellx, Inc. The transactions occurred on April 28, 2026, and involved the cancellation and conversion of stock options as part of a merger agreement with Gilead Sciences, Inc. The options were converted into a right to receive a cash payment based on the difference between a closing amount of $115 per share and the option's exercise price, plus one contingent value right per share. All reported stock options were acquired prior to the merger and were either vested or unvested, with exercise prices below $115. Following the merger, the number of shares owned by the reporting person decreased to zero as the options were converted. The filing indicates that these transactions were not subject to Section 16 of the Securities Exchange Act of 1934.